<sup>68</sup>Ga-PSMA and <sup>68</sup>Ga-DOTA-RM2 PET/MRI in Recurrent Prostate Cancer: Diagnostic Performance and Association with Clinical and Histopathological Data.

Cancers (Basel) · 2022 · PMC8773792 · PMID 35053499

Europe PMC DOI

hedged sentence

0.0650

closest p · 1.3× alpha

0.0650

boldest claim

The sentences

approached the level of significancep = 0.065so close (0.05 < p ≤ 0.1)

Accordingly, we reported that patients having a PSA DT ≥ 6 months present a significantly lower number of lesions compared to those having a faster rise in PSA levels after primary treatment; we observed the same trend on a patient-based analysis, although after adjustment for multiple testing, the p -value only approached the level of significance ( p = 0.065).

also in 48 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.